Bookmark

Add to MyYahoo RSS

Cubist Pharmaceuticals News

News on Cubist Pharmaceuticals (Ticker: CBST) continually updated from thousands of sources around the net.

Tuesday Jul 1 | BayStreet.ca

Cidara Therapeutics - "Back to the Rodeo"

New York, NY / ACCESSWIRE / July 1, 2014 / Cidara Therapeutics today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, Dr. Jeff Stein.

Comment?

Related Topix: Biotech, Cubist Pharmaceuticals, Medicine, Healthcare Industry

Mon Jun 30, 2014

Freshnews

Cidara Therapeutics Completes $32 Million Series A Financing

SAN DIEGO, Calif. -- -- Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company's Cloudbreak targeted immunotherapy platform and biafungin, a novel long acting echinocandin antifungal drug, into human ... (more)

Comment?

Related Topix: Venture Capital, Emerging Technology, Harvard University, Biotech, Cubist Pharmaceuticals, Medicine, Healthcare Industry, Infectious Diseases

Sun Jun 29, 2014

Seeking Alpha

Cepheid Developing A Rapid Diagnostic Test For Multidrug-Resistant Superbugs

In late January, I recommended that investors buy the molecular diagnostics company Cepheid just below $47, with 25% near term upside.

Comment?

Related Topix: Startups, Cepheid, Infectious Diseases, Medicine, Biotech, GlaxoSmithKline, AstraZeneca Group, Cubist Pharmaceuticals, Healthcare Industry

Mon Jun 23, 2014

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

The report is available at 'www.fitchratings.com'. Additional information is availabl... Resumen: SIVEXTRO de Cubist ha sido aprobado en Estados Unidos para el tratamiento de infecciones graves de la piel, incluidas aquellas causadas por SARM )--Cubist Pharmaceuticals, Inc. ha comunicado que la FDA ha aprobado SIVEXTROTM para el tratamiento de las ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Food and Drug Administration

AmericanBankingNews.com

Cubist Pharmaceuticals's "Positive" Rating Reaffirmed at Aegis

's stock had its "positive" rating reiterated by equities research analysts at Aegis in a research note issued to investors on Monday.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

TheStreet.com

Will This Price Target Increase Help Cubist Pharmaceuticals (CBST) Stock Today?

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Mozilla, TheStreet

Pharmaceutical Processing

FDA Approves Cubist Antibiotic for Skin Infections

The Food and Drug Administration on Friday approved a new antibiotic from Cubist Pharmaceuticals to treat common skin infections often acquired in the hospital.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Healthcare Law, Law, Food and Drug Administration, Cubist Pharmaceuticals, Marketing

Fri Jun 20, 2014

The Washington Post

Cubist Wins U.S. FDA Approval for MRSA Antibiotic Sivextro

Cubist Pharmaceuticals Inc. won U.S. approval for its antibiotic Sivextro to treat acute bacterial skin infections, including potentially fatal MRSA.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, MRSA, Health, Food and Drug Administration, Centers for Disease Control and Prevention, Business News

Forbes.com

Antibiotic Pipeline Revival: FDA Approves Cubist...

Late this afternoon, the U.S. Food and Drug Administration approved Cubist Pharmaceuticals' tedizolid phosphate for the treatment of acute adult bacterial skin and skin structure infections, or ABSSSIs.

Comment?

Related Topix: Healthcare Law, Food and Drug Administration, Law, Biotech, Medicine, Healthcare Industry, MRSA, Health, Emerging Technology, Search Engines, Zyvox, Linezolid (generic)

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Les presentations de ... )--EY today announced the winners of EY Entrepreneur Of The YearTM Award in San Diego.

Comment?

Related Topix: Concord EFS, Financial Services, Biotech, Medicine, Healthcare Industry, Food and Drug Administration, Schlumberger, Energy, Oil & Gas, Food, Hormel Foods Corporation

Business Journal

Approval of Cubist's newest skin infection drug expected by day's end

Sivextro will be administered intravenously at first, then through a pill, for a total of six days, a shorter duration than current drugs on the market.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Food and Drug Administration, Cubist Pharmaceuticals

AmericanBankingNews.com

Cubist Pharmaceuticals Coverage Initiated at Gabelli

Cubist Pharmaceuticals opened at 68.55 on Friday. Cubist Pharmaceuticals has a 1-year low of $48.23 and a 1-year high of $82.12.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

Thu Jun 19, 2014

Theflyonthewall.com

Targa, Targa Resources Partners terminate talks with Energy Transfer Equity

Targa, Targa Resources Partners terminate talks with Energy Transfer Equity Targa Resources and Targa Resources Partners announced that they have previously engaged in high level preliminary discussions regarding a potential business combination with Energy Transfer Equity and certain of its affiliates, but that those discussions have been ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Tibco Software, Loyalty Lab, TIBCO Software

Customer Interaction Solutions

Cubist Announces Acceptance of Ceftolozane/Tazobactam New Drug Application with Priority Review

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic ceftolozane/tazobactam with Priority Review.

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Healthcare Industry, Urinary Tract Infections, Health, E. Coli, Infectious Diseases

BioSpace

Cepheid And Leading Pharmaceutical Companies Partner On A Diagnostic...

Targeting bacterial infections with the right treatment will slow the development of resistance that has led to a crisis in treating infections.

Comment?

Related Topix: Startups, Marisa Christina, Apparel, Cepheid, Biotech, Medicine, Healthcare Industry, Infectious Diseases, Centers for Disease Control and Prevention

Mon Jun 16, 2014

BioSpace

Cubist Pharmaceuticals, Inc. Selects TransPerfect Trial...

TransPerfect, a leading provider of e-clinical solutions and language services to the life sciences industry, today announced that Cubist has selected Trial Interactive as their electronic Trial Master File enterprise solution across several clinical programs.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, TransPerfect

Fri Jun 13, 2014

The Motley Fool

3 Reasons Why Shorts Are Moving into Durata Therapeutics

Because short-sellers are exposed to potentially unlimited losses, they tend to be cautious in choosing their targets.

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Healthcare Industry

Wed Jun 11, 2014

Hispanic Business

Cubist to Present at June Investor Conferences

About is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••